Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

NP-DNA-NDDS

Financiado

Cerrado

Multifunctional theranostic nanoparticles using pH responsive DNA nanoparticle c...

Multifunctional theranostic nanoparticles using pH responsive DNA nanoparticle conjugate for effective cancer therapy Cancer is a leading cause of death worldwide, accounting for 7.6 million deaths in 2008. Although conventional cancer chemotherapy can provide profound benefits, seriously adverse side-effects still cannot be avoided, due to lack... ver más

30/09/2015

UNIVLEEDS

309K€

Presupuesto del proyecto: 309K€

Líder del proyecto

UNIVERSITY OF LEEDS No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2015-09-30 No tenemos la información de la convocatoria

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

UNIVLEEDS

0.00€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

TheranoXome Engineered Exosomes for Stimuli-responsive Image-guided Drug... 181K€ Cerrado

SAF2016-75241-R NANOMATERIALES PARA TERAPIAS DIRIGIDAS CONTRA EL CANCER VISU... 133K€ Cerrado

PCIN-2017-042 NANOTRANSPORTADORES POLIPEPTIDICOS SENSIBLES A LA TEMPERATUR... 138K€ Cerrado

HeatNMof Heating triggered drug release from nanometric inorganic met... 3M€ Cerrado

PIcelles Penetration promoting and Imageable Polymeric Micelles as a... 150K€ Cerrado

PID2020-118448RB-C22 DESARROLLO DE NANOSISTEMAS MULTIFUNCIONALES BASADOS EN METAL... 121K€ Cerrado

Líder del proyecto

UNIVERSITY OF LEEDS No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 309K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Cancer is a leading cause of death worldwide, accounting for 7.6 million deaths in 2008. Although conventional cancer chemotherapy can provide profound benefits, seriously adverse side-effects still cannot be avoided, due to lack of specific targeting nature of current treatments. Nanomedicine can reduce such side-effects by exploiting characteristic properties of tumors for targeted delivery and therapy. Despite extensive research, most nanomedicines developed so far have relied on passive targeting using a single therapeutic modality, which are inefficient for treatment of challenging conditions such as multi-drug resistance. Recently we developed a pH-responsive-DNA-GNP conjugate based nanocarrier that numerous features required for an ideal drug nanocarrier, e.g. uniform small nanoscale size, resisting non-specific adsorption, non-toxic, biocompatible, water-soluble, stable, and having high drug loading and controlled release capacities. It can offer efficient and pH-triggered drug release suitable for effective cancer chemotherapy at the cellular level using doxorubicin, a widely used chemotherapy drug. Herein we will extend it into a more effective, multifunctional nanomedicine that can offer simultaneous biomodal chemotherapies with hyperthermia and MRI imaging capacities. First, we will prepare, characterize, and evaluate their drug loading & release profiles in buffer; then we will study and quantify their cell- & cell-specific- uptake and drug delivery efficiency, and then evaluate their toxicity, cytotoxicity & cell-specific cytotoxicity with cancer cells (incoming phase), and finally evaluate their synergistic therapeutic efficacy at cellular and preclinical level (re-integration phase). This project will greatly benefit both the fundamental research in nanomedicine and the healthcare/pharmaceutical indurstries in Europe.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores